Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20181026041471N1
IRCT20181026041471N1
Recruiting
Phase 3

Evaluating the effect of dapagliflozin on preventing contrast-associated acute kidney injury in patients with acute coronary syndrome undergoing angiography (DARIUS); a multicenter, randomized, double-blind, placebo-controlled clinical trial

Rajaie Cardiovascular Medical and Research Institute0 sites1,500 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAcute Coronary Syndrome.ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Acute Coronary Syndrome.
Sponsor
Rajaie Cardiovascular Medical and Research Institute
Enrollment
1500
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Rajaie Cardiovascular Medical and Research Institute

Eligibility Criteria

Inclusion Criteria

  • •Patients over 18 years old hospitalized with acute coronary syndrome (i.e. ST elevation or NST elevation myocardial infarction or unstable angina) diagnosis and candidates for coronary angiography or angioplasty
  • •Signed informed consent to participate in the study

Exclusion Criteria

  • •Patients previously treated with SGLT2 inhibitor drugs
  • •Creatinine clearance less than 25 ml/min
  • •Chronic liver disease and cirrhosis (Child\-Pugh C)
  • •Drug allergy or history of severe hypersensitivity to dapagliflozin or its components
  • •Non\-consent to participate in the study
  • •History of recurrent urinary tract infections
  • •History of ketoacidosis
  • •Pregnancy or breastfeeding
  • •Type 1 diabetes mellitus

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2016-003897-41-PLAstraZeneca AB4,500
Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionMedDRA version: 20.0 Level: PT Classification code 10007558 Term: Cardiac failure chronic System Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2016-003897-41-DKAstraZeneca AB4,500
Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2016-003897-41-BGAstraZeneca AB4,500
Active, Not Recruiting
Phase 1
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.
EUCTR2016-003897-41-SEAstraZeneca AB4,500
Completed
Phase 3
DAPA-HFChronic Heart Failure With Reduced Ejection Fraction (HFrEF)
JPRN-jRCT2080223469AstraZeneca KK330